DDInter204 DDInter1435
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Bicalutamide {u} (Compound) treats {v} (Disease) prostate cancer
Bicalutamide {u} (Compound) binds {v} (Gene) AR
Bicalutamide {u} (Compound) upregulates {v} (Gene) USP6NL
Bicalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Bicalutamide {u} (Compound) downregulates {v} (Gene) TUBB6
Bicalutamide {u} (Compound) causes {v} (Side Effect) Melaena
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Bicalutamide (Compound) resembles Enzalutamide (Compound)
Bicalutamide (Compound) treats prostate cancer (Disease)
Bicalutamide (Compound) binds AR (Gene)
Bicalutamide (Compound) upregulates USP6NL (Gene)
Bicalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class)
Bicalutamide (Compound) downregulates TUBB6 (Gene)
Bicalutamide (Compound) causes Melaena (Side Effect)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine